Consolidated net sales for the interim period were 142,254 million yen (Year-over-Year 9.0% increase), operating income was 12,745 million yen (YoY 22.0% increase), and interim net income attributable to owners of parent was 6,866 million yen (YoY -16.4% decrease). By segment, domestic sales were 111,477 million yen and overseas sales were 31,134 million yen, with strong growth overseas. Full-year earnings guidance remains unchanged. Dividends are maintained at 40 yen at the end of the second quarter and a full-year forecast of 85 yen. Plans to expand production capacity through collaborations such as with Tanabe Pharma Factory are underway.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4553-20261111-02.pdf","jir_short_summary":"Consolidated net sales for the interim period were 142,254 million yen (Year-over-Year 9.0% increase), operating income was 12,745 million yen (YoY 22.0% increase), and interim net income attributable to owners of parent was 6,866 million yen (YoY -16.4% decrease). By segment, domestic sales were 111,477 million yen and overseas sales were 31,134 million yen, with strong growth overseas. Full-year earnings guidance remains unchanged. Dividends are maintained at 40 yen at the end of the second quarter and a full-year forecast of 85 yen. Plans to expand production capacity through collaborations such as with Tanabe Pharma Factory are underway.","jir_summary":"### Overview of Performance\nThis financial summary reports consolidated results for the second quarter of the fiscal year ending March 2027. Net sales were 142,254 million yen (YoY 9.0% increase) and operating income was 12,745 million yen (YoY 22.0% increase), reflecting steady performance. Ordinary income decreased to 10,093 million yen (YoY -15.7%) due to factors including derivative valuation losses, and interim net income attributable to owners of parent was 6,866 million yen (YoY -16.4%). By segment, revenue increased to 111,477 million yen domestically and 31,134 million yen internationally.\n\n### Outlook and Impact for Investors\nFull-year earnings guidance is maintained, and the dividend policy continues with 40 yen per share at the end of the second quarter and a full-year plan of 85 yen for the fiscal year ending March 2027. The company aims to secure future supply stability and growth by expanding production capacity and strengthening collaborations both domestically and internationally. Notably, expansion of overseas operations and capacity increases through strategic partnerships such as with Tanabe Pharma Factory are key focus areas.","jir_financial_highlights":"Net Sales: 142,254 (YoY 9.0% increase)\nOperating Income: 12,745 (YoY 22.0% increase)\nOrdinary Income: 10,093 (YoY -15.7% decrease)\nInterim Net Income Attributable to Owners of Parent: 6,866 (YoY -16.4% decrease)\nEquity Ratio: 39.6% (Up 2.1 percentage points from fiscal year-end)","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #Earnings, #Interim, #Generics, #Collaboration","jir_key_figures":"Net Sales: 142,254 million yen (YoY 9.0% increase)\nOperating Income: 12,745 million yen (YoY 22.0% increase)\nInterim Net Income: 6,866 million yen (YoY -16.4% decrease)","jir_meta_title":"Towa Pharmaceutical Co., Ltd. Interim Results\uff5cNet Sales +9%, Operating Income +22%, Dividend Policy Maintained","jir_meta_description":"Summary of Towa Pharmaceutical Co., Ltd.'s second quarter results for the fiscal year ending March 2027. Net sales: 142,254 million yen; operating income: 12,745 million yen; net income: 6,866 million yen. Notes on overseas expansion, production capacity plans, and dividend policy.","jir_og_title":"Towa Pharmaceutical Co., Ltd.: Key Points from Interim Results","jir_og_description":"Towa Pharmaceutical Co., Ltd.'s second quarter results for the fiscal year ending March 2027. Net sales: 142,254 million yen; operating income: 12,745 million yen. Confirmation of overseas expansion and dividend policy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-03\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[130476,142254]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-03\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[10443,12745]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Interim Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-03\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Interim Net Income\\\",\\\"data\\\":[8214,6866]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic\\\",\\\"Overseas\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[111477,31134]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Margin Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-03\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Margin\\\",\\\"data\\\":[10.0,8.97]}]},\\\"options\\\":{}}\"}]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149182","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n